Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment

Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment

High-dose isoniazid is recommended to treat multidrug-resistant tuberculosis (MDR TB). Among 958 MDR TB isolates identified in France during 2008–2022, 93.1% exhibited high-level isoniazid resistance, and molecular testing showed limited diagnostic accuracy in predicting resistance. Clinicians shou...

Full description

Saved in:
Bibliographic Details
Main Authors: Valentina Gerussi, Tania Petersen, Isabelle Bonnet, Alexandra Aubry, Marwa Bachir, Esther Gyde, Florence Morel, Corentin Poignon, Brigitte Rached, Valérie Pourcher, Christophe Rioux, Dorothée Vallois, Nicolas Veziris, Jérôme Robert, Lorenzo Guglielmetti
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2025-03-01
Series:Emerging Infectious Diseases
Subjects:
tuberculosis and other mycobacteria
bacteria
respiratory infections
MDR TB
isoniazid
inhA
Online Access:https://wwwnc.cdc.gov/eid/article/31/3/24-1473_article
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://wwwnc.cdc.gov/eid/article/31/3/24-1473_article

Similar Items